Plasma Neprilysin for Predicting Sepsis Within 48 Hours in ICU Patients With Infection or Suspected Infection
Key facts
- Who runs it
- Zhujiang Hospital
- Where
- China2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- People taking part
- 488 people, planned
- Started
- 1 Aug 2026
- Expected to end
- 30 Apr 2028
- Type of study
- Observational
- Treatments tested
- Plasma Neprilysin Measurement
- Conventional Sepsis Biomarker Measurement
- Sublingual Microcirculation Assessment
- Record updated
- 1 September 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Age 18 years or older
- Confirmed or suspected infection as assessed by the treating physician based on symptoms, signs, laboratory findings, imaging findings, microbiological findings, or evidence of an infection source, with systemic antimicrobial therapy initiated or planned
- Does not meet the protocol-defined criteria for sepsis at enrollment. In the setting of confirmed or suspected infection, there must be no acute increase of 2 or more points in the Sequential Organ Failure Assessment 2 score from baseline that is attributable to infection
- Expected by the treating physician to remain in the intensive care unit for more than 48 hours after enrollment
- Written informed consent provided by the participant or the participant's legally authorized representative
Who cannot take part
- Sepsis diagnosed at intensive care unit admission or fulfillment of the Sepsis-3 criteria at screening
- Insufficient clinical data to determine the baseline SOFA-2 score according to the prespecified assessment criteria
- Patients with limited nursing care (patients for whom active treatment has been withdrawn)
- No blood sample is available on the day of enrollment
- Considered unsuitable for participation by the investigator
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this multicenter prospective observational cohort study is to determine whether plasma neprilysin can predict the development of sepsis within 48 hours in adults admitted to an intensive care unit with confirmed or suspected infection who do not have sepsis at enrollment.
Read full original descriptionShow less
The study will be conducted at Zhujiang Hospital, Southern Medical University, and Guangzhou First Municipal People's Hospital. Plasma samples remaining after routine clinical testing will be used to measure neprilysin and conventional sepsis biomarkers. Sublingual microcirculation will also be assessed when feasible.
Participants will be assessed for the development of sepsis from enrollment through 48 hours and will be followed for survival through Day 28. No treatment or clinical intervention will be assigned by the study protocol.
The group in the trial
- ICU Participants With Infection or Suspected Infection
Adults admitted to the intensive care unit with confirmed or suspected infection who do not meet the protocol-defined criteria for sepsis at enrollment. Participants will be observed for the development of sepsis through 48 hours and followed for survival through Day 28.
Treatment: Plasma Neprilysin Measurement, Conventional Sepsis Biomarker Measurement, and Sublingual Microcirculation Assessment
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Plasma Neprilysin for Early Prediction of Sepsis Within 48 Hours in ICU Patients With Infection or Suspected Infection (NEPSIS): A Multicenter Prospective Cohort Study
- Record updated
- 1 September 2026